Global Short Bowel Syndrome (SBS) Market Size, Status and Forecast 2019-2025

2 Global Short Bowel Syndrome (SBS) Quarterly Market Size Analysis

• 2.1 Short Bowel Syndrome (SBS) Business Impact Assessment - COVID-19
  • 2.1.1 Global Short Bowel Syndrome (SBS) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Short Bowel Syndrome (SBS) Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Short Bowel Syndrome (SBS) Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Short Bowel Syndrome (SBS) Headquarters and Area Served
• 3.3 Date of Key Players Enter into Short Bowel Syndrome (SBS) Market
• 3.4 Key Players Short Bowel Syndrome (SBS) Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Short Bowel Syndrome (SBS) Segments, By Type

• 4.1 Introduction
  • 1.4.1 Oral Route
  • 1.4.2 Parental Route
• 4.2 By Type, Global Short Bowel Syndrome (SBS) Market Size, 2019-2021

5 Impact of Covid-19 on Short Bowel Syndrome (SBS) Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals
  • 5.5.2 Clinics
  • 5.5.3 Retail Pharmacies
• 5.2 By Application, Global Short Bowel Syndrome (SBS) Market Size, 2019-2021
  • 5.2.1 By Application, Global Short Bowel Syndrome (SBS) Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Merck
  • 7.1.1 Merck Business Overview
  • 7.1.2 Merck Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.1.3 Merck Short Bowel Syndrome (SBS) Product Introduction
  • 7.1.4 Merck Response to COVID-19 and Related Developments
• 7.2 Takeda
  • 7.2.1 Takeda Business Overview
  • 7.2.2 Takeda Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.2.3 Takeda Short Bowel Syndrome (SBS) Product Introduction
  • 7.2.4 Takeda Response to COVID-19 and Related Developments
• 7.3 Emmaus Medical
  • 7.3.1 Emmaus Medical Business Overview
  • 7.3.2 Emmaus Medical Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.3.3 Emmaus Medical Short Bowel Syndrome (SBS) Product Introduction
  • 7.3.4 Emmaus Medical Response to COVID-19 and Related Developments
• 7.4 Ardelyx
  • 7.4.1 Ardelyx Business Overview
  • 7.4.2 Ardelyx Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.4.3 Ardelyx Short Bowel Syndrome (SBS) Product Introduction
  • 7.4.4 Ardelyx Response to COVID-19 and Related Developments
• 7.5 Naia Pharmaceuticals
  • 7.5.1 Naia Pharmaceuticals Business Overview
  • 7.5.2 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.5.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Product Introduction
  • 7.5.4 Naia Pharmaceuticals Response to COVID-19 and Related Developments
• 7.6 Nutrinia
  • 7.6.1 Nutrinia Business Overview
  • 7.6.2 Nutrinia Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.6.3 Nutrinia Short Bowel Syndrome (SBS) Product Introduction
  • 7.6.4 Nutrinia Response to COVID-19 and Related Developments
• 7.7 OxThera
  • 7.7.1 OxThera Business Overview
  • 7.7.2 OxThera Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.7.3 OxThera Short Bowel Syndrome (SBS) Product Introduction
  • 7.7.4 OxThera Response to COVID-19 and Related Developments
• 7.8 Sancilio Pharmaceuticals
  • 7.8.1 Sancilio Pharmaceuticals Business Overview
  • 7.8.2 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.8.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Product Introduction
  • 7.8.4 Sancilio Pharmaceuticals Response to COVID-19 and Related Developments
• 7.9 Zealand Pharma
  • 7.9.1 Zealand Pharma Business Overview
  • 7.9.2 Zealand Pharma Short Bowel Syndrome (SBS) Quarterly Revenue, 2020
  • 7.9.3 Zealand Pharma Short Bowel Syndrome (SBS) Product Introduction
  • 7.9.4 Zealand Pharma Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US